Improving productivity of modern-day drug discovery

Expert Opinion on Drug Discovery

Volumn 9, Issue 2, 2014, Pages 115-118

  Breyer, Matthew D ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Animal model; Clinical trial; Experimental design; Human disease

Indexed keywords

MESSENGER RNA;

ANIMAL MODEL; DISEASE COURSE; DRUG DETERMINATION; DRUG DEVELOPMENT; DRUG INDUSTRY; EXPERIMENTAL DESIGN; HEALTH CARE COST; HEREDITY; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PRODUCTIVITY; REVIEW; THERAPY EFFECT; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS;

EID: 84893100457     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2014.870150     Document Type: Review

References (30)

1. Munos B. Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov 2009;8(12):959-68
2. Kaitin KI, DiMasi JA. Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009. Clin Pharmacol Ther 2011;89(2):183-8
3. Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov 2012;11(3):191-200
4. Arrowsmith J. Trial watch: phase ii failures: 2008-2010. Nat Rev Drug Discov 2011;10(5):328-9
5. Arrowsmith J, Miller P. Trial watch: phase ii and phase iii attrition rates 2011-2012. Nat Rev Drug Discov 2013;12(8):569-9
6. Rice J. Animal models: not close enough. Nature 2012;484(7393):S9
7. Seok J, Warren HS, Cuenca AG, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA 2013;110(9):3507-12
8. Hackam DG, Redelmeier DA. Translation of research evidence from animals to humans. JAMA 2006;296(14):1731-2
9. Murray CJ, Lopez AD. Measuring the global burden of disease. N Engl J Med 2013;369(5):448-57
10. Duffy MJ, McGowan PM, Crown J. Targeted therapy for triple-negative breast cancer: where are we? Int J Cancer 2012;131(11):2471-7
11. Wilkinson T. From disease heterogeneity through patient endotype to "microtype": the future for chronic obstructive pulmonary disease research? Am J Respir Crit Care Med 2012;185(6):686-7
12. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366(10):883-92
13. Asslaber M, Abuja PM, Stark K, et al. The genome austria tissue bank (gatib). Pathobiology 2007;74(4):251-8
14. Collins SM, McHugh K, Croitoru K, Howorth M. The establishment of a national tissue bank for inflammatory bowel disease research in canada. Can J Gastroenterol 2003;17(2):107-9
15. Hodgin JB, Nair V, Zhang H, et al. Identification of cross-species shared transcriptional networks of diabetic nephropathy in human and mouse glomeruli. Diabetes 2013;62(1):299-308
16. Woroniecka KI, Park AS, Mohtat D, et al. Transcriptome analysis of human diabetic kidney disease. Diabetes 2011;60(9):2354-69
17. Church DM, Goodstadt L, Hillier LW, et al. Lineage-specific biology revealed by a finished genome assembly of the mouse. PLoS Biol 2009;7(5):e1000112
18. Lindblad-Toh K, Wade CM, Mikkelsen TS, et al. Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature 2005;438(7069):803-19
19. Gharib WH, Robinson-Rechavi M.When orthologs diverge between human and mouse. Brief Bioinform 2011;12(5):436-41
20. Sambrook JG, Beck S. Evolutionary vignettes of natural killer cell receptors. Curr Opin Immunol 2007;19(5):553-60
21. Monajemi H, Fontijn RD, Pannekoek H, Horrevoets AJG. The apolipoprotein l gene cluster has emerged recently in evolution and is expressed in human vascular tissue. Genomics 2002;79(4):539-46
22. Freedman BI, Kopp JB, Langefeld CD, et al. The apolipoprotein l1 (apol1) gene and nondiabetic nephropathy in african americans. J Am Soc Nephrol 2010;21(9):1422-6
23. Ginsberg SD, Alldred MJ, Che S. Gene expression levels assessed by ca1 pyramidal neuron and regional hippocampal dissections in alzheimer's disease. Neurobiol Dis 2012;45(1):99-107
24. Ramsey BW, Banks-Schlegel S, Accurso FJ, et al. Future directions in early cystic fibrosis lung disease research: an nhlbi workshop report. Am J Respir Crit Care Med 2012;185(8):887-92
25. Cohen TS, Prince A. Cystic fibrosis: a mucosal immunodeficiency syndrome. Nat Med 2012;18(4):509-19
26. Friedman SL, Sheppard D, Duffield JS, Violette S. Therapy for fibrotic diseases: nearing the starting line. Sci Transl Med 2013;5(167):167sr161
27. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 2012;18(7):1028-40
28. Constantinidou A, Jones RL, Reis-Filho JS. Beyond triple-negative breast cancer: the need to define new subtypes. Expert Rev Anticancer Ther 2010;10(8):1197-213
29. Rashid OM, Nagahashi M, Ramachandran S, et al. Is tail vein injection a relevant breast cancer lung metastasis model? J Thorac Dis 2013;5(4):385-92
30. Fidler IJ. The biology of cancer metastasis. Semin Cancer Biol 2011;21(2):71